

# DISC4 ReMIND-L Program GWG Recommendations



Gil Sambrano, PhD

Vice President, Portfolio Development  
and Review

August 29, 2024

# Our Mission

---

Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.

---



# ReMIND Initiative: Goals & Objective

Research using **Multidisciplinary, Innovative approaches**  
in **Neuro Diseases**

**Accelerate** the **discovery of mechanisms** underlying **neuropsychiatric** disorders leading to **identification** and **validation** of novel **targets** and **biomarkers** with the goal to provide new avenues and rigorous foundations for future translational and clinical investigations

- **Accelerate** foundational scientific understanding of disease mechanisms, and development of transformative tools and technologies
- **Catalyze** multi-disciplinary innovation, attract new talent and seed new partnerships
- **Drive** open and collaborative science through data, resource & knowledge sharing

# ReMIND: Two Unique Award Types

	ReMIND-L	ReMIND-X
<b>Types of study</b>	Large collaborative projects	Exploratory, high-risk projects
<b>Duration</b>	4 years	2 years
<b>Max budget</b> Direct Project Costs	\$10M (with matching funds) \$8M (without matching funds)	\$1M
<b>CA eligibility</b>	California non-profit or for-profit research institutions	
<b>Core team</b>	min 5 investigators 1 Principal and 4 co-Investigators	min 2 investigators 1 Principal and 1 co-Investigator
<b>Number of awards</b>	6	12
<b>RFA posted</b>	Dec 2023	TBD

# ReMIND-L Program Outcomes

**ReMIND-L** awards will support expansive, cross-disciplinary and integrated studies led by large collaborative teams applying a range of technologies and approaches.

## Outcomes of proposed projects may include:

- **Discover** novel mechanistic insights or further our current understanding of neuropsychiatric disease mechanisms
- **Address** major bottlenecks in the study of neuropsychiatric disorders
- **Expand** understanding of disease mechanisms to diverse human populations
- **Identify** and **validate** new therapeutic hypotheses, targets, and/or biomarker(s)

# ReMIND-L Program Requirements

**Address a key knowledge gap or research bottleneck  
in our understanding of neuropsychiatric diseases**

**Include studies that employ stem cells or genetic\* research  
as part of the central approach or hypothesis**

**Justify any proposed use of non-human models  
and validate findings using human tissue or models**

\* Research that alters genomic sequences of cells (edit, remove or add DNA sequences); or introduces or directly manipulates nucleic acids (e.g., coding and non-coding RNAs, antisense oligonucleotides) in cells

# ReMIND-L Program Requirements

	<b>ReMIND-L</b>
<b>Applicant Organization</b>	<b>California-based non-profit or for-profit</b> research institutions
<b>Principal Investigator</b>	<b>Single PI</b> to serve as the primary administrative contact for CIRM and effectively manage overall team
<b>Core Team</b>	<b>Minimum 5 investigators</b> 1 Principal and 4 or more co-Investigators
<b>Minimum % effort</b>	Principal Investigator – 15% Co-Investigators (4 or more) – 10% each
<b>Other personnel requirements</b>	<ul style="list-style-type: none"> <li>• At least one member with relevant clinical expertise</li> <li>• At least one member with relevant computational biology expertise</li> <li>• Data project manager</li> </ul>

# ReMIND-L Program Requirements

Additional funds up to \$0.5M/year can be requested **IF** equal or larger amount of matching funds is provided


## Matching Funds

<b>Requirements</b>	<ul style="list-style-type: none"> <li>• Must be contributed evenly across the award period</li> <li>• Must be used for specific project related expenses</li> <li>• Evidence of commitment of funds must be provided at pre-funding admin review</li> </ul>
<b>Source of Funds</b>	<ul style="list-style-type: none"> <li>• Any CA or non-CA non-CIRM source (with funder approval)</li> <li>• May include in-kind contributions (value must be justified)</li> </ul>
<b>Eligible Expenses</b>	<ul style="list-style-type: none"> <li>• Salary for full-time personnel</li> <li>• Research supplies and resources uniquely dedicated to this project</li> <li>• Use of facilities with existing recharge rates</li> <li>• Third-party subcontracts</li> </ul>
<b>Application Sections</b>	<ul style="list-style-type: none"> <li>• Online Matching Funds page</li> <li>• Research Proposal and Budget Justification upload documents</li> <li>• May upload supporting documents at application stage if available</li> </ul>




# GWG Composition and Roles

Scientific GWG  
Member




Scientific evaluation (disease or technology expertise)  
Provides scientific score on all applications

GWG Board  
Member



Patient perspective on DEI, significance and potential  
impact, oversight on process  
Provides a suggested scientific score

Scientific Specialist  
(non-voting)



Scientific evaluation (specialized expertise as needed)  
Provides initial but not final scientific score

# ReMIND Scoring System

- **Score of “1”**

*Exceptional merit and warrants funding.*

*May have minor recommendations and adjustments that do not require further review by the GWG*

- **Score of “2”**

*Needs improvement and does not warrant funding at this time but may be resubmitted to address areas for improvement. CIRM’s board may opt to allow resubmissions if fewer than the target number of applications are funded in the first round.*

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding.*

# Scientific Review Criteria

## Basis for Scientific Score

1. Does the project hold the necessary significance and potential for impact?
2. Is the proposal innovative?
3. Is the rationale sound?
4. Is the project well planned and designed?
5. Is the proposal feasible?
6. Does the project uphold the principles of diversity, equity, and inclusion?

# GWG Recommendations

Score	Number of Apps	Total Applicant Request	Funds Available
<b>Warrants funding</b> Score of "1"	5	\$67,524,203	\$88,200,000
<b>Needs improvement</b> Score of "2"	9	\$112,208,322	
<b>Does not warrant funding</b> Score of "3"	12		

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.

# Minority Reports

- Under Prop 14, any application that is not recommended for funding by the GWG, but which had 35% or more members score to fund the application must include a minority report.
- The minority report is included in the review summary and provides a brief synopsis of the opinion of reviewers that scored the application 85 or above.

# Applications with Minority Report

App Number	Title	Funds Requested	Score	Number of Votes		
				1	2	3
<b>DISC4-16337</b>	Defining Neurovascular Metabolism in Neurodevelopmental and Neuropsychiatric Disorders	<b>\$12,000,482</b>	2	7	7	0

The CIRM Team supports the majority position for application DISC4-16337 to not fund but allow applicants to revise and resubmit.

# Applications with Score of “2”

- Nine applications received a score of “2”, which allows resubmission if the target number of applications (6) is not reached, **and** the Application Review Subcommittee agrees to consider additional applications for funding.
- The remaining budget allows funding of one additional application and possibly two, if applicants reduce their requested budget.
- The CIRM team recommends:
  - Approve funding for the 5 applications with a score of “1”
  - Do not approve funding of all applications with a score of “3”
  - Allow for revision and resubmission of applications with a score of “2”